• Agendia will present new FLEX study data at the ASCO Annual Meeting in Chicago on May 29–June 2, 2026.
• Two posters are scheduled for June 1, 2026, including results linking MammaPrint High Risk 2 tumors to higher homologous recombination deficiency scores, supporting treatment selection in HR+HER2- early-stage breast cancer.
• A second June 1 poster will show that combining BluePrint molecular subtyping with the ImPrint immune signature improved prediction of pathologic complete response in HER2+ early-stage breast cancer treated with neoadjuvant dual HER2 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agendia NV published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.